



Xellia Pharmaceuticals to focus on the manufacturing and commercialization of its life-saving anti-infectives portfolio through its global B2B partners

Copenhagen, Denmark, 17 June 2024—Xellia Pharmaceuticals ('Xellia'), a global leader in specialty anti-infective treatments and critical care therapies, is pleased to announce the divestment of its US-based institutional activities to Hikma Pharmaceuticals (Hikma), a leading global supplier of generic injectables.

The transaction includes the Cleveland manufacturing site, the in-market institutional commercial portfolio based in Chicago, the drug product R&D pipeline, and the R&D site in Zagreb, Croatia.

The divestment follows a strategic decision, where an enhanced focus on the manufacturing and commercializing of fermentation-based APIs for anti-infectives, along with a selected range of finished dose forms for the global B2B market, will pave the way for a resilient and prosperous future, ensuring Xellia's continued provision of life-saving products to patients worldwide.

This strategic pivot opens a new chapter in Xellia's 120-year legacy, solidifying the company's position as a significant supplier and service provider of life-saving anti-infectives to the global B2B market.

Michael Kocher, CEO at Xellia Pharmaceuticals, said:

The divestment of our US-based institutional business to Hikma is a defining milestone in the transformation journey we embarked on almost nine months ago. By focusing on our core strengths, we are positioning Xellia for a robust and prosperous future, enabling us to continue to deliver life-saving products to patients worldwide.

With a broad and complementary portfolio of injectables, Hikma is the right home for our existing critical care therapies in the US. This transaction will unlock the full potential and continue to save patients' lives.

The transaction is subject to customary closing conditions.

Leerink Partners is acting as exclusive financial advisor to Xellia. K&L Gates LLP is serving as legal advisor to Xellia.

- Ends -

For more information, please contact:

Xellia Pharmaceuticals

Regitze Reeh, Vice President Corporate Communications & Public Affairs

Regitze.Reeh@xellia.com

Instinctif Partners (International media relations)

Melanie Toyne-Sewell / Katie Duffell / Feaven Abidta

+44 (0) 20 7457 2020

xellia@instinctif.com